Healthcare Professionals Click HereE-mail to a FriendPrint
You need to upgrade your Flash Player This is replaced by the Flash content. Place your alternate content here and users without the Flash plugin or with Javascript turned off will see this. Content here allows you to leave out noscript tags. Include a link to bypass the detection if you wish.

KINRIX is indicated for the fifth DTaP and fourth dose IPV in 4 to 6 year olds whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX.

Important Safety Information

In clinical studies, common adverse events were injection-site reactions (pain, redness, swelling, or increase in arm circumference), drowsiness, fever, and loss of appetite. Previous hypersensitivity to any component of KINRIX, including neomycin and polymyxin B, is a contraindication. Encephalopathy within 7 days of administration of a previous pertussis-containing vaccine or a progressive neurologic disorder is a contraindication. The decision to give KINRIX should be based on potential benefits and risks, if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, or if adverse events have occurred in temporal relation to receipt of a pertussis-containing vaccine. The needleless, prefilled syringes contain dry natural latex rubber and may cause allergic reactions. For children at higher risk for seizures, an antipyretic may be administered at the time of vaccination. Vaccination with KINRIX may not protect all individuals who received the vaccine.

Infanrix® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed)

Pediarix® [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined]

KINRIX is a trademark of GlaxoSmithKline.
Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium
Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709